Acromegaly and Vitamin D Metabolism: Effect of Bromocriptine Treatment

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 1979 Sep 1

PMID 468984

Citations 11

Authors

P C Eskildsen

O H Sorensen

B Lund

J E Bishop

A W Norman

Affiliations

Soon will be listed here.

Abstract

Fifteen acromegalic subjects were found to have elevated plasma levels of both 1,25(OH)2-vitamin D, 65 +/- 23 (SD) pg/ml [normal 33 + 15 pg/ml (SD)] and 24,25(OH)2-vitamin D, 6.8 +/- 1.6 (SD) ng/ml [normal 3.4 + 1.2 ng/ml (SD)]. Treatment with bromocriptine for 6 months reduced the plasma 1,25(OH)2-vitamin D3 level to 40 +/- 13 (SD) pg/ml, p less than 0.01 and the 24,25(OH)2-vitamin D level to 5.4 +/- 1.7 (SD) ng/ml, p less than 0.05.

Citing Articles

Vitamin D in pituitary driven osteopathies.

Chiloiro S, Costanza F, Riccardi E, Giampietro A, De Marinis L, Bianchi A Pituitary. 2024; 27(6):847-859.

PMID: 39180644 PMC: 11632065. DOI: 10.1007/s11102-024-01439-3.

Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment.

Povaliaeva A, Bogdanov V, Zhukov A, Pigarova E, Dzeranova L, Rozhinskaya L Endocrine. 2022; 76(2):407-418.

PMID: 35138562 DOI: 10.1007/s12020-022-02994-0.

Vitamin D and the kidney.

Kumar R, Tebben P, Thompson J Arch Biochem Biophys. 2012; 523(1):77-86.

PMID: 22426203 PMC: 3361542. DOI: 10.1016/j.abb.2012.03.003.

Current status and future opportunities for controlling acromegaly.

Melmed S, Vance M, Barkan A, Bengtsson B, Kleinberg D, Klibanski A Pituitary. 2003; 5(3):185-96.

PMID: 12812311 DOI: 10.1023/a:1023369317275.

Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Legovini P, De Menis E, Breda F, Billeci D, Carteri A, Pavan P J Endocrinol Invest. 1997; 20(8):434-8.

PMID: 9364245 DOI: 10.1007/BF03347998.